Metformin Intake Suppresses The Degree of Liver Metastasis From Colorectal Cancer In Diabetic Patients But Does Not Improve Their Prognosis

Background: Metformin reduces the risk of, and mortality from, colorectal cancer in patients with diabetes mellitus. However, the effect of metformin on patients with stage IV disease is unknown. In the present study we reviewed the clinical features and outcomes of patients with diabetes mellitus and stage IV colorectal cancer (M1, liver metastases) treated with or without metformin. Methods: The 202 patients with colorectal cancer and macroscopic liver metastasis who were treated in the Department of Surgery or Department of Clinical Oncology at Jichi Medical University Hospital from January 2006 through June 2019 were surveyed treatment of diabetes, clinical and pathological factor and prognosis of these patients. Results: We retrospectively examined the effect of metformin use on outcomes in 32 patients with liver metastases from colorectal cancer. Hepatic metastases were stage H1 in 8/8 patients taking metformin and stage H2-3 in 17/24 non-users. Of 22 patients who underwent colectomy, colorectal tumors were pT4 in 5 metformin users, and pT2-3 in 10/17 non-users. The mean survival of metformin users and non-users was equal (28.0 mo vs 29.3 mo, p>.05). No signicant difference was detected when survival was compared between 6 metformin users and 19 non-users who received systemic chemotherapy. Conclusion: These results suggest that metformin has less potent anti-tumor effects in patients with advanced stage disease. Metformin for the treatment of patients with metastatic colorectal cancer requires further study.

advanced stage disease. Metformin for the treatment of patients with metastatic colorectal cancer requires further study. Backgroud Type 2 diabetes mellitus (DM) is well known to increase the risk for development of various cancers, including colorectal cancer (CRC) [1][2][3]. Metformin, an oral anti-hyperglycemic agent, has been shown to reduce the incidence of cancer development among patients with type 2 DM, although the degree of reduction varies among different types of cancer [4][5][6]. Many epidemiologic studies have suggested that that metformin may also improve the outcome of patients with CRC [6-10], although a large populationbased study did not support a signi cant association between metformin and cancer-speci c mortality [11]. There is clear evidence that outcome of the diabetic patients who underwent curative surgery with stage II and III CRC is associated with better survival in metformin-users [9,[12][13][14][15]. However, survival bene t is less clear in patients with stage IV CRC. In fact, a retrospective study focused on the patients who received chemotherapy for stage IV CRC has shown that tumor response, change in target lesion size as well as patient outcome were not signi cantly different between the metformin treated and the nontreated patients [16]. In this study, therefore, we examined the clinical features and outcome of diabetic patients with satge IV CRC with liver metastases who were treated with or without metformin.

Methods
From January 2006 until June 2019, 202 CRC patients with liver macroscopic metastases were treated in the Department of Surgery or Department Clinical Oncology at Jichi Medical University Hospital. Among them, 32 patients (16 %) suffered type 2 DM and received medical treatment at diagnosis. In these patients, data for gender, age, medical history, treatment method, laboratory and pathological data and outcome were extracted from an electronic database. The stage of metastatic hepatic tumors was classi ed into the three categories with the number of liver nodules and the size of the largest metastasis: H1, ≤4 lesions and ≤5 cm; H2, ≥5 lesions or >5 cm; and H3, ≥5 lesions and >5 cm, according to criteria of the Japanese Society for Cancer of the Colon and Rectum [17]. This study was approved by the ethics committee of the Jichi University Hospital (approval no. clinic19-190) and was conducted in accordance with the guiding principles of the Declaration of Helsinki.
Statistical differences in clinical and pathological factors were evaluated with Fisher's exact test. Overall survival (OS) was calculated using the Kaplan-Meier method and differences were evaluated using the log-rank test. In all tests, the standard for a signi cant difference was set at p < 0.05.

Results
As shown in Table 1, 8 patients (25%) were treated with medications including metformin, 500mg~1000mg daily from 1 to 23 year (median=7 year), while other 24 patients were not exposed to metformin at diagnosis. No differences were detected in age, gender, tumor location and metastases in other sites between metformin-users and non-users. However, the degree of liver metastasis was all H1 stage in 8 metformin-users, while H2~3 stage in more than half (13/24) of non-usres ( p<0.018). with FOLFIRI and 1 with SOX and 2 with capecitabibe. No signi cant difference was detected even when overall survival was evaluated in patients who received chemotherapy (MST:42.8 mo vs 29.3 mo, p=0.96).

Discussion
A growing body of evidence indicates that metformin have anti-tumor effects through various mechanisms including reduction of viability and proliferation of tumor cells, repression of epithelialmesenchymal transition as well as modulation of tumor immuneenviromnet [18,19]. In this study, we found that grade of liver metastasis in CRC patients was limited in H1 stage even though pT stage of primary tumor was more advanced in all metformin-users. This is consistent with the results of previouos studies and supports the anti-metastatic effects of metformin. We previously reported that the number of nodal metastases was signi cantly lower in metformin-treated CRC patients with diabetes [15]. Taken together, these data susggest a possibility that metformin inhibits tumor metastasis not only at primary sites but also suppresses the growth of tumor cells in metastatic organs.
Epidemiological studies have suggested that metformin not only reduces the risk of developing CRC but also improve the outcome of diabetic patients, especially in those who underwent curative surgery with stage II and III CRC [6-10, [12][13][14][15]. Interestingly, however, the impact of metformin intake on the outcome of the stage IV patients has not been clearly documented in previous literatures and and therapeutic effect of metformin in metastatic CRC still remains unclari ed. In this study, we could not found apparent survival bene t of metformin intake in CRC patinets liver metastases, although H stage was less advanced in metformin-users. This is is consistent with a previous korean study [16], and suggest a possibility that anti-tumor effects of metformin is less prominent in advanced stage of CRC, although the sample sizes in both studies are not enough to draw a de nite conclusion.
In fact, a number of basic studies have shown metformin can sensitize tumor responses to different chemotherapeutic drugs through various molecular mechanisms [20]. Many clinical trials are currently active to examine the synergistic effect of metformin on chemotherapeutic agents for various cancers [21]. In CRC, metformin has been shown to enhance the effects of adjuvant chemotherapy [22,23]. In comparison, the effects of metformin on 5-Fu based chemotherapy for refractory CRC was reported to be modest [24]. Extensive randomized control trials will be necessary to con rm the real therapeutic potential of metformin for stage IV CRC.

Conclusions
These results suggest that metformin has less potent anti-tumor effects in patients with advanced stage disease. Metformin for the treatment of patients with metastatic colorectal cancer requires further study. This study protocol was reviewed and approved by the Ethics Committee of the Jichi Medical University Hospital (approval no. clinicA20-110) and was conducted in accordance with the guiding principles of the Declaration of Helsinki.

Consent for publication
Not applicable Availability of data and materials All data generated or analysed during this study are included in this published article.

Competing interests
The authors declare that they have no competing interests.

Funding
This research received no speci c grant from any funding agency in the public, commercial, or not-forpro t sectors.

Author Contributions
Joji Kitayama: Analyzed and interpreted the data. Akira Saito: Analyzed and interpreted the data and wrote the paper.
Hideyuki Ohzawa: Contributed analysis tools or data.
Hironori Yamaguchi: Analyzed and interpreted the data.